Welcome to our dedicated page for Capricor Therapeutics news (Ticker: CAPR), a resource for investors and traders seeking the latest updates and insights on Capricor Therapeutics stock.
Capricor Therapeutics develops cell and exosome-based therapeutics for rare diseases, with Deramiocel, an allogeneic cardiac-derived cell therapy, as its lead program for Duchenne muscular dystrophy. Company news commonly covers HOPE-3 clinical data, Biologics License Application communications with the FDA, regulatory designations for Deramiocel, and manufacturing activities tied to the DMD program.
Updates also include financial results, corporate presentations at neurology and muscular dystrophy medical meetings, collaboration revenue references tied to its U.S. Distribution Agreement with Nippon Shinyaku, and preclinical work using the StealthX exosome platform for vaccinology and delivery of oligonucleotides, proteins, and small-molecule therapeutics.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Capricor Therapeutics (NASDAQ: CAPR) announced the publication of a preclinical study in Microbiology Spectrum, showcasing the potential of its StealthX™ exosome platform to develop a multivalent vaccine targeting SARS-CoV-2 proteins. The study indicates that engineered exosomes expressing SARS-CoV-2 spike and nucleocapsid proteins can induce strong immune responses. Notably, the combination approach (STX-S+N) demonstrated robust antibody production and T-cell response with minimal protein doses, lacking adjuvants. CEO Linda Marbán highlighted the significance of this platform in generating potentially superior vaccines. The results support further exploration of the StealthX™ platform in expanding Capricor's therapeutic pipeline, especially concerning rapidly evolving viruses.
Capricor Therapeutics (NASDAQ: CAPR) reported promising 18-month results from its HOPE-2 open-label extension study for CAP-1002, aimed at treating Duchenne muscular dystrophy (DMD). Presented by Dr. Craig McDonald at the Muscular Dystrophy Association Clinical & Scientific Conference, the findings show statistically significant improvements in the Performance of the Upper Limb (PUL version 2.0) scale (p=0.02) compared to the placebo group. Both groups showed reduced disease progression after starting treatment. CAP-1002 maintained a good safety profile, and the study indicates potential long-term benefits for patients. The company is advancing to the HOPE-3 Phase 3 trial.
Capricor Therapeutics (NASDAQ: CAPR) reports progress in its HOPE-3 Phase 3 trial for CAP-1002 in Duchenne Muscular Dystrophy (DMD), with enrollment exceeding 30% and an interim analysis expected in Q4 2023. The company also engaged with the FDA for a Biologics License Application (BLA) pathway. A partnership with Nippon Shinyaku expands its DMD franchise in Japan, yielding $12 million upfront and potential milestones of $89 million. Financially, Q4 2022 revenue was approximately $1 million, with a net loss of $7.7 million. Capricor's cash and equivalents totaled $41.4 million, sufficient to fund operations into Q4 2024.
Capricor Therapeutics (NASDAQ: CAPR) will announce its financial achievements for the fourth quarter and full year 2022 on March 15, 2023, following the market close. The company is expected to discuss its developments regarding CAP-1002, its leading candidate for treating Duchenne muscular dystrophy, currently in late-stage clinical trials. A conference call is scheduled for 4:30 p.m. ET on the same day to discuss the results and recent corporate updates. Investors can access the live webcast and replay through the company’s website.
Capricor Therapeutics (NASDAQ: CAPR) announced that its HOPE-2 trial for Duchenne muscular dystrophy using lead asset CAP-1002 has received the 2023 Top Ten Clinical Research Achievement Award from the Clinical Research Forum. This recognition highlights significant advancements in clinical research and underscores the promising results from the trial. Dr. Linda Marbán, CEO of Capricor, emphasized the commitment to bringing CAP-1002 closer to market. The award ceremony is scheduled for April 17, 2023, in Washington, D.C. DMD affects approximately 200,000 boys and young men globally, with limited treatment options available.